Targeting a blood stem cell subset shows lasting gene editing 31 July 2019 | By Drug Target Review Scientists report how editing a portion of stem cells with CRISPR-Cas9 is sufficient for long-term reactivation of therapeutic haemoglobin.
Newly discovered signal could lead to anti-cancer therapies 31 July 2019 | By Drug Target Review Researchers have newly found that protein CD24 acts as a defensive signal and is used by cancer cells to protect themselves.
Researchers discover new neuroblastoma drug target 31 July 2019 | By Victoria Rees (Drug Target Review) A study has discovered that reducing expression of a key gene in neuroblastoma tumourigenesis is an important drug target for the condition.
Study of TP53 mutations shows insight into the gene’s function 31 July 2019 | By Drug Target Review New study sheds light on how the TP53 gene becomes mutated and how those mutations can help predict clinical outlooks for cancer.
New therapy discovered to treat acute lymphoblastic leukaemia 30 July 2019 | By Drug Target Review Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
Study identifies potential drug target for prostate cancer 30 July 2019 | By Victoria Rees (Drug Target Review) Researchers have discovered a non-coding RNA which could be used as a biomarker and in new therapies for prostate cancer.
New discovery could lead to new treatments for Parkinson’s 30 July 2019 | By Drug Target Review New discovery makes it possible to design new therapies to replace alpha-synuclein's function in people with Parkinson's disease.
Two therapeutic targets identified for lung cancer 30 July 2019 | By Drug Target Review Salk scientists discover a pair of enzymes that drive non-small-cell lung cancer by promoting inflammation which could inform the development of new therapies.
New molecule developed to fight microRNA-related disease 30 July 2019 | By Drug Target Review Newly developed HDO-antimiR could lead to new ways to treat diseases which are caused by malfunctioning miRNAs.
No-cut CRISPR could be used to treat muscular dystrophy 29 July 2019 | By Victoria Rees (Drug Target Review) Researchers have successfully used a no-cut CRISPR gene editing technique as a therapy for muscular dystrophy in mice models.
Screening identifies gene which protects cells from Zika virus 26 July 2019 | By Victoria Rees (Drug Target Review) Researchers used screening to discover genes that protect the body against the Zika virus, which could inform potential therapies against the virus.
Study discovers key process in the cause of cell aging 26 July 2019 | By Victoria Rees (Drug Target Review) Researchers have identified a key process behind senescence, or why cells age, which could be used to improve treatments for cancer.
New system enables improved pre-clinical testing of heart drugs 26 July 2019 | By Drug Target Review Researchers have extended the life of heart segments from 24 hours to six days, enabling pre-clinical trials to experiment on these new models for longer periods of time.
Treatment for Lafora disease shows promise in pre-clinical study 25 July 2019 | By Victoria Rees (Drug Target Review) A novel antibody-enzyme fusion therapeutic strategy for Lafora disease has shown effectiveness in pre-clinical study mice models.
Scientists control living cells using artificial protein switch 24 July 2019 | By Drug Target Review Scientists have created the first completely artificial protein switch that can be ‘programmed’ to modify gene expression.
